H. Böck

[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].

W. Hiddemann, C. Pott, S. Hermann, 2002, Deutsche medizinische Wochenschrift.

Clinical Trials and Observations

W. Hiddemann, M. Qumsiyeh, H. Einsele, 2005 .

Harvesting of Peripheral Blood Progenitor Cells with Different Programmes of Discontinuous Flow Systems

G. Brittinger, H. Böck, M. Uppenkamp, 1999, Vox Sanguinis.

Rituximab maintenance following a rituximab containing chemotherapy significantly prolongs the duration of response in patients with relapsed follicular and mantle cell lymphomas: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)

W. Hiddemann, M. Dreyling, M. Gramatzki, 2005 .

Harvesting of Peripheral Blood Progenitor Cells with Different Programmes of Discontinuous Flow Systems

G. Brittinger, H. Böck, M. Uppenkamp, 1999, Vox sanguinis.

Rituximab maintenance improves progression-free and overall survival rates after combined immuno-chemotherapy (R-FCM) in patients with relapsed follicular and mantle cell lymphoma: Final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).

W. Hiddemann, K. Wilms, U. Dührsen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.